Close
  Indian J Med Microbiol
 

Figure 1: Timeline of major milestones in the field of pharmacotherapeutics for age-related macular degeneration. In the figure, a number of landmark randomized clinical trials that have brought a paradigm change in the management of neovascular age-related macular degeneration, and led to the approval (by United States Food and Drug Administration) of therapeutic agents such as ranibizumab and aflibercept, among others, have been chronicled. The month and the year of the studies refer to the publication date of the primary endpoint manuscript

Figure 1: Timeline of major milestones in the field of pharmacotherapeutics for age-related macular degeneration. In the figure, a number of landmark randomized clinical trials that have brought a paradigm change in the management of neovascular age-related macular degeneration, and led to the approval (by United States Food and Drug Administration) of therapeutic agents such as ranibizumab and aflibercept, among others, have been chronicled. The month and the year of the studies refer to the publication date of the primary endpoint manuscript